BioMark Receives Approval for Its Lung Cancer Treatment Protocol
VANCOUVER, British Columbia, March 29, 2016 (GLOBE NEWSWIRE) -- BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE:BUX) (FSE:20B) (OTCQB:BMKDF) is pleased to announce that it has now completed its response to lung cancer treatment protocol and has …